Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.48% | 7.90% | 3.84% | -0.34% | 2.30% |
| Total Other Revenue | 41.92% | 43.24% | 64.98% | 36.43% | 17.39% |
| Total Revenue | 18.59% | 9.29% | 5.92% | 0.99% | 2.89% |
| Cost of Revenue | 16.62% | 15.29% | 16.09% | 11.95% | 13.18% |
| Gross Profit | 20.92% | 2.61% | -4.75% | -9.97% | -7.08% |
| SG&A Expenses | 1.67% | -1.12% | -6.34% | -8.61% | -6.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 100.00% | -- | -- | -- | -1,900.00% |
| Total Operating Expenses | 12.83% | 10.76% | 9.56% | 5.81% | 7.27% |
| Operating Income | 34.29% | 5.49% | -3.33% | -10.69% | -7.40% |
| Income Before Tax | 10.53% | 5.97% | 3.46% | 9.43% | 3.54% |
| Income Tax Expenses | 53.31% | 101.18% | 51.27% | 97.60% | 80.09% |
| Earnings from Continuing Operations | 5.23% | -2.91% | -1.69% | 2.09% | -1.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.23% | -2.91% | -1.69% | 2.09% | -1.64% |
| EBIT | 34.29% | 5.49% | -3.33% | -10.69% | -7.40% |
| EBITDA | 29.86% | 5.27% | -1.97% | -8.26% | -5.44% |
| EPS Basic | 8.14% | 0.38% | 1.85% | 5.49% | 0.50% |
| Normalized Basic EPS | 54.31% | 28.63% | 22.09% | 15.45% | -2.54% |
| EPS Diluted | 8.42% | 1.93% | 4.45% | 8.53% | 3.36% |
| Normalized Diluted EPS | 54.80% | 30.60% | 24.98% | 18.56% | 0.11% |
| Average Basic Shares Outstanding | -2.74% | -3.32% | -3.46% | -3.08% | -1.76% |
| Average Diluted Shares Outstanding | -3.18% | -4.76% | -5.61% | -5.65% | -4.28% |
| Dividend Per Share | 40.15% | 106.82% | 306.82% | -- | -- |
| Payout Ratio | 0.31% | 1.09% | 3.06% | -- | -- |